Clinical Trial Update: Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating multi-antigen specific CD8+ T cells with decitabine and lymphodepleting chemotherapy for relapsed or refractory acute myeloid leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Decitabine (Decitabine)
• Fludarabine (Fludarabine)
• Multi-antigen Specific CD8+ T Cells

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1 | Status: WITHDRAWN